Medically reviewed by the Celva medical team · June 2026
The most technical section in this library. Where MSCs actually come from cord vs. bone marrow vs. fat. Allogeneic vs. autologous. What "cGMP-compliant lab" really means. How a batch of cells is tested before any of it reaches a patient. And the single most important sentence in this whole library: "stem cells" from one clinic are not the same product as "stem cells" from another.
Prefer to watch?
Short on time? The video makes the whole case in one pass: where the cells come from, how they're tested, and why two vials labeled "stem cells" can be entirely different products. Keep scrolling for the full version.
Read in order, this section moves from "stem cells" are not the same product → cord vs. bone vs. fat → allogeneic vs. autologous → cGMP, in practice → counts, viability, dose → the testing panel before infusion.
Begin with the part of the brochure that almost no clinic prints: the words "stem cell" cover a range of products as wide as the word "drug." Aspirin and chemotherapy are both drugs. Cord-derived MSCs, expanded under cGMP and characterized against the ISCT panel, and a vial of adipose-derived stromal vascular fraction prepared bedside in a centrifuge, are both stem cell therapy.
The difference is not a slogan. It is measurable. Source tissue determines the proliferative and immunomodulatory profile. Donor screening determines what else might be inside the vial. Passage number determines how senescent the population has become. Manufacturing the lab, the media, the QC, determines whether the headline cell count corresponds to anything the patient can actually use.
This section walks you through each of those variables, in the order in which they matter. By the end of it, the phrase "we use stem cells" should sound to you the way "we use medicine" sounds to a physician: true, but not informative. The right questions are the next layer down. We try to answer all of them, in writing, before you ever sit in a chair.
The questions to ask before you accept a quote, in order. Source. Identity. Verification. Each is the subject of at least one article below; each is also, on its own, a sufficient reason to walk away from a clinic that cannot answer.
Three tissues yield MSCs. Cord (umbilical), bone marrow, adipose. They are not interchangeable. Cord-derived cells are younger, more proliferative, and more immunomodulatory. Bone marrow yields the best-characterized cells in the literature but requires an invasive harvest. Adipose-derived stromal vascular fraction, prepared bedside, is the source most often misrepresented as "stem cell therapy."
The International Society for Cellular Therapy minimum criteria. Plastic adherent. Positive for CD73, CD90, CD105. Negative for the hematopoietic markers CD45 and CD34, plus HLA-DR. Tri-lineage differentiation potential in vitro. If a clinic cannot show you flow cytometry against this panel for the lot you are receiving, the word "MSC" on the consent form is decorative.
A released lot must pass six independent assays before any vial leaves the lab. Sterility (no bacteria/fungi); identity (the ISCT panel); viability (≥95% by 7-AAD); potency (a functional assay, not a count); endotoxin; mycoplasma. The certificate of analysis is the only document that matters. It's available on request through your case coordinator.
What this section will not do. Tell you which source is "best." The answer depends on the indication and the patient. Tell you that allogeneic is universally superior to autologous, or vice versa. The interesting answer is when each applies. Below, six articles in the order we wrote them.
MSCs initiate a signaling cascade that operates at six levels at once. Together these mechanisms address the upstream biology behind chronic conditions, changing the environment so the body's own repair capacity can function again. The signaling persists well beyond the cells themselves.
Reduces the chronic inflammatory signaling that contributes to pain, dysfunction, and progressive tissue damage, systemically.
Attenuates the fibrotic cascade that replaces functional tissue with scar tissue, a downstream consequence of chronic inflammation.
Recalibrates dysregulated immune activity across the body without systemic immune suppression.
Supports formation of new vascular networks, contributing to tissue perfusion and a more favorable systemic repair environment.
Releases growth factors (BDNF, NGF, GDNF) that support neuronal survival and protect nerve tissue from chronic inflammatory damage.
Signals stressed, at-risk host cells to survive rather than die, mediated by factors like HGF and IGF-1, preserving tissue that chronic inflammation would otherwise lose.
These six mechanisms are active regardless of cell source. What varies, and what the physician team optimizes, is which cell type, dose, and delivery method produces the strongest expression of these mechanisms for a given indication.
Celva's physician team at Hospital Angeles, Tijuana does not use a single cell product across all patients. Source, biology, and mechanism expression are matched to the indication, delivery route, and clinical goal. All three are manufactured in our own cGMP lab at Hospital Angeles, using proprietary culture media, expansion methods, and protocols developed in-house and used nowhere else. Most clinics, in Tijuana or Cancún, don't run a lab at all; they buy frozen vials from a third-party supplier. Ours are screened to the same identity standards and released against the same panel. The cell type that ends up in the dose is the clinical decision.
Donated cord tissue, full-term healthy births. Cells with a robust secretome, higher anti-inflammatory cytokine expression and stronger immunomodulatory activity per cell than adult-derived cells. The preferred choice for systemic IV protocols, neurologic indications, and autoimmune cases where broad immune and inflammatory recalibration is the primary goal.
Adult allogeneic donors. Bone marrow aspirate, expanded under cGMP, screened to the same identity standards as UC-MSCs. More lineage-committed than UC-MSCs, biased toward musculoskeletal tissue types: stronger anti-fibrotic and pro-angiogenic expression in chronically inflamed joints. Not the autologous "same-day bone marrow" product offered at most U.S. clinics; this is a donor-sourced, expanded, batch-released product.
Chondrocyte-lineage cells, allogeneic, no harvest required from the patient. Unlike MSCs (which act primarily through signaling), chondrocytes are structurally oriented. They produce the collagen and proteoglycan matrix that forms cartilage. In depleted cartilage environments, they provide matrix-building capacity MSCs alone cannot replicate. Added alongside BM-MSCs in select cartilage cases, most useful where some cartilage matrix remains.
How the call is made. Cell selection is a clinical decision made during physician-team review, not a product the patient picks at intake. Target tissue, mechanism priority, delivery route, the structural-versus-signaling question, and the evidence base for the specific case all inform it. In many cases, a combination protocol (UC-MSCs systemically alongside BM-MSCs and chondrocytes at the target site) produces a more complete response than any single cell type alone. The cell type is part of the protocol, not a product on a menu.
Each article is written to stand alone, but they were designed to be read in sequence. Article 3.1 is the foundation: if you only read one piece in this whole library, read that one.
The single most important sentence in this library. Why two clinics offering "stem cell therapy" can be offering radically different products. and the four variables that account for almost all of the variance.
The three tissues from which MSCs are actually harvested, and why the source matters more than most patients realize. Yield, proliferative potential, donor screening, and the practical implications for an infusion you receive in 2026.
Donor cells versus your own. The trade-offs, the data, and what each approach is actually good for in 2026. Why the answer for orthopedic indications is not the answer for systemic inflammation, and why the marketing rarely says so.
Three letters that get used as a marketing prop everywhere. What they actually refer to, what compliance entails on the ground, and the practical questions to ask, including the ones that separate a cGMP suite from a clean room with good lighting.
How a "dose" of mesenchymal stem cells is actually measured. Why two products labeled 100 million cells are not the same dose. Live cells vs. total cells, the viability denominator, the difference between a count on paper and a count at the bedside.
Every assay run on a batch of cells before it reaches a patient. Sterility, identity, viability, potency, residual contaminants. What each test is for, what passing looks like, and which document you should be asking your clinic to put in your hands.
Stromal vascular fraction prepared bedside from a patient's own fat is a different product from cultured, characterized allogeneic MSCs. Both can be called "stem cell therapy." Only one passes the ISCT identity panel. We sell the latter. If you want the former, there are clinics for that, but you should know what you're buying.
The ISCT panel is run on every working cell bank and on release of every clinical lot. Not on the master bank ten years ago. If a clinic shows you a single flow plot from 2019 and calls it characterization, the answer is that the lot in front of you has not been characterized.
A headline count is a denominator. The numerator is viable cells with intact identity and function. A vial of 100M cells at 60% viability with no potency assay is not equivalent to a vial of 50M cells at 95% viability with a documented immunomodulatory assay. We publish all four numbers per lot.
MSCs are immunomodulators and paracrine signalers, not regenerative engines that rebuild lost tissue. They lower inflammatory cytokines, shift macrophage polarization, support endogenous repair. That is what the literature supports. Anything you read here that sounds bigger than that is in the wrong document. Email us.